Pharma Focus America’s Post

Forbion portfolio company Enterprise Therapeutics Ltd (Enterprise), a #biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of those suffering from respiratory disease, announced dosing of the first person with cystic fibrosis (pwCF) in its Phase 2a trial of ETD001. ETD001, a low molecular weight compound with first-in-class potential, targets the epithelial sodium channel (ENaC) in the airway epithelium to increase the hydration and clearance of mucus. The Phase 2a trial aims to deliver clinical proof-of-concept and to assess the safety profile of ETD001 in the 10% of pwCF with the highest unmet medical need. The study will be performed at sites located in UK, Germany, France and Italy and will assess lung function (FEV1) in pwCF who are either ineligible for or are not receiving CFTR modulators. Read more using the following link: https://lnkd.in/gJGmZaN8 #clincialtrial #lifesciences #biotech #discovery #development #cysticfibrosis #respiratory Geert-Jan Mulder John Ford

Don’t miss the scientific insights of our own William Boomershine, Ph.D. in his exclusive article in The Medicine Maker, Navigating the Analytical Complexity of Oligonucleotide Therapeutics. In it, he shares how to overcome the analytical complexities inherent to oligonucleotide manufacturing, which can unlock untold health benefits of valuable new patient therapies and vaccines. Read the full article ➡️ https://hubs.li/Q02Rvgcb0 #Alcami #TheMedicineMaker #Oligonucleotides #biopharma #pharma #AskAlcami

Novapep Pty Ltd is developing its patented peptide called biparetide, a revolutionary molecule aimed at treating inflammatory bowel disease (IBD) and atopic dermatitis. Partnering with leading institutions including the Florey Institute, Auspep, and Formulytica, Novapep aims to initiate Phase 1 clinical trials within the next two years. Preclinical data shows biparetide’s efficacy in IBD is on par with anti-TNF⍺ therapies at a fraction of the cost, and it outperforms corticosteroids.  It is as effective in treating atopic dermatitis as corticosteroids, without their side effects. With a patent secured until 2039 and a strong management team led by Prof. John Griffin, Dr Meagan Walsh and Jay Hennock, Novapep is poised to make a significant impact in the biopharmaceutical industry. Investment Offering 💰 Funding Offer: $1 million Safe Note on an $8.5 million cap valuation, fully diluted. Participation: Follow-on investment from Sydney Angels and existing investors. Structure: Safe Note Investment into a trust vehicle with certain shareholder rights. Future Plans: Last funding round before the Series A, targeting institutional investors. Register your interest with Novapep here: https://lnkd.in/gDkfEr3V Steve Torso #Biopharmaceutical #InvestmentOpportunities #SeriesA #Australia #AngelInvestors #VC 

As we enter the final months of #IPST’s 25th anniversary and continue our ongoing series of posts covering the different stages of preclinical drug development, let’s dive into the topic of #PK/PD: The primary objective of PK-PD (pharmacokinetic-pharmacodynamic) studies is to clarify the complex relationship between a drug's concentration in the body (pharmacokinetics) and its corresponding pharmacological effects (pharmacodynamics). By thoroughly investigating this interplay, these studies refine dosing regimens and administration routes of lead drug candidates, enabling critical adjustments that are essential for advancing drug development. This process provides researchers with valuable insights into the drug's behavior in the body and its therapeutic outcomes, ultimately optimizing its administration strategy for continued progression through the development pipeline. To explore further or discuss potential collaborations, please reach out to us. info@ipstherapeutique.com #drugdiscovery #PAH #IPF #heartfaailure #cardiovascular #coagulation #fibrosis #liverfibrosis

🌟 Columbus Venture Partners brings exciting news and updates about our portfolio companies! 🌟 🏆 Co-Founder and Chief Scientific Officer of Vivet Therapeutics, Gloria Gonzalez-Aseguinolaza has been honored with the prestigious Rosalind Franklin Society (RFS) Special Award in Science 🔬 for her remarkable contributions and dedication to advancing scientific knowledge. 🚀 Artax Biopharma Inc has updated information on their candidate pipeline and the progress they are making in the development of AX-158 and AX-194 for #autoimmunediseases, #psoriasis, and #atopicdermatitis. Learn more here: https://lnkd.in/d_RrncBp 💡 Integra Therapeutics will receive up to €10.5 million from the European Commission for their advanced therapies platform #FiCAT through the #eicAccelerator program. ℹ More information: https://lnkd.in/dB_WXPqD 🔬 QUATRE LAB explains the benefits of outsourcing to CROs for the bio-pharmaceutical industry, addressing the complexities of rare diseases more effectively and ensuring innovative treatments reach patients faster. 🔍 To read the full article, visit: https://lnkd.in/d4xbxmQc 𝗖𝗼𝗻𝗴𝗿𝗮𝘁𝘂𝗹𝗮𝘁𝗶𝗼𝗻𝘀 𝘁𝗼 𝗮𝗹𝗹 𝗼𝗳 𝘆𝗼𝘂! #biotech #innovation #healthcare #pharmaceuticals #research #ColumbusVP #investment #AdvancedTherapies #GeneTherapy #GeneWriting #CRISPR #clinicaltrials #immunology

Clene Inc. (NASDAQ: CLNN), a biopharmaceutical company focused on improving mitochondrial health, recently presented its achievements at the H.C. Wainwright 26th Annual Global Investment Conference. The company highlighted its lead drug candidate, CNM-Au8, which has shown promise in restoring and protecting neurological function for neurodegenerative conditions. Clene Nanomedicine, Inc. is seeking FDA approval to file a new drug application for CNM-Au8, utilizing the accelerated approval pathway for the treatment of amyotrophic lateral sclerosis (ALS). The company's management presented recent results and plans for CNM-Au8 during the conference, held virtually from Sept. 9-11. 'We are excited about the potential of CNM-Au8 to provide new hope for patients with neurodegenerative diseases,' said Rob Etherington, President and CEO of Clene. 'The data so far is encouraging, and we look forward to advancing this promising therapeutic candidate.' #neurodegenerative #als #ms #biotech IBN (InvestorBrandNetwork)

Proteolysis Targeting Chimeras (PROTACs) are taking the pharmaceutical world by storm, targeting disease-causing proteins previously considered “undruggable.” But preclinical development isn’t straightforward—unique challenges in pharmacokinetics, safety, and bioavailability can slow progress if not addressed early. Here, we break down these barriers and share strategies to bring these therapies to patients who need them most. Click to see how these challenges are managed. https://hubs.li/Q030yWv-0 #DrugDiscovery #PROTAC #PharmaceuticalResearch #PreclinicalTesting #TargetedTherapies

🔇 Exciting advancements in AI-based #peptidedesign are here with Insilico Medicine's Generative Biologics app! This video demonstrates the streamlined process of designing alpha-helical peptides using cutting-edge #AIgorithms. Simply upload your target PDB, and the app automatically identifies the binding site. From there, specify your peptide length and experiment duration, hit 'Run,' and within hours, you receive a bunch of peptides designed specifically to bind your target. This innovative approach simplifies peptide design and accelerates research—an essential tool for advancing #biopharmaceutical development!

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, recently participated in two investor conferences to present updates on its lead drug candidate, CNM-Au8®. The company gave a fireside presentation at the 2024 Maxim Healthcare Virtual Summit on October 15 and will present at The ThinkEquity Conference 2024 on October 30 in New York. CNM-Au8® has shown promising results in restoring and protecting neurological function, offering hope for patients with amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions. Clene is seeking an accelerated approval pathway for CNM-Au8 for ALS and is scheduled to meet with the FDA leadership in November. The company's focus on improving mitochondrial health and protecting neuronal function has garnered interest from investors, as CNM-Au8® targets a crucial aspect of neurodegenerative diseases. @clene_inc's participation in these conferences highlights its commitment to keeping investors informed about its progress and achievements. #biotechnology #neurodegenerative #investorconferences #clnn @clene_inc

🚀 Are you attending #TIDES2024 in Hamburg, Germany, November 11-14? Let’s connect at booth #316! Our experts, Cátia Teixeira and Luísa Aguiar, are excited to share how our PurePep solutions can elevate your peptide projects to the next level. 💡 The peptide therapeutics landscape is rapidly evolving, driven by two major trends: ⭐ Innovative Screening Platforms: Chemical and display screening platforms are becoming the new standard for target-based drug development, enriching the preclinical pipeline significantly. ⭐ GLP-1 Analogs Success: The breakthrough in GLP-1 analogs for weight loss and obesity is transforming pharmaceutical interest in peptides, leading to high demand and a capacity crunch in synthesis. We’re here to help you navigate these changes—see you in Hamburg! #purepep #forpeptidescientists #synthesis #purification